【1】把握海外進駐新商機 7/20-26媒合國際生技巨擘

把握海外進駐新商機 7/20-26媒合國際生技巨擘

今年再次熱情參與的吹灌封技術(Blow-Fill-Seal)全球領先者Rommelag AG,又新增了提供全球CDMO技術AGC Biologics、擁有50年豐富經驗Bachem AG、致力於標靶治療和診斷的 Molecular Targeting Technologies、提供先進儀器Thermo Fisher Scientific、創新粒線體療法LUCA Science Inc.、擁有專利基因編輯技術C4U Corporation、致力於新藥開發ABVC BioPharma等實力大廠,期盼7/20-26的國際生技巨擘媒合中,能碰撞出新刺激,帶來不一樣的國際觀點與潛力無限的商機!



Rommelag is the inventor and global leader in aseptic filling systems using blow-fill-seal (BFS) technology. Our bottelpack packaging systems are considered advanced aseptic filling by regulatory authorities. The BFS containers are formed from plastic polymer material in an automated process, filled and hermetically sealed. With its BFS packaging solutions for sterile liquids (e.g. eye drops, infusion solution, injectables, inhalations, vaccines), gels and ointments, Rommelag is present in the pharmaceutical, healthcare, but also in the cosmetic as well as the chemical industries.


Bio-Techne Hong Kong Limited

Bio-Techne empowers researchers in Life Science and Clinical Diagnostics by providing high-quality reagents, instruments, custom manufacturing, and testing services. Our family of brands creates a unique portfolio of products and services.
Science is our passion; it drives us to collaborate, develop, and manufacture award-winning tools that help researchers achieve reproducible and consistent results. Whether you are at the cutting edge of academic research, translating basic discoveries to therapeutic leads, or at a facility that requires the highest level of diagnostic testing, our innovative products and services provide the solutions you need to achieve success.


AGC Biologics

AGC Biologics is a global CDMO with seven facilities worldwide providing end-to-end process development and manufacturing services for drug substances and advanced therapies. From development to clinical trials, to full-scale commercialization, we can help you reach your goals at any stage in the development or manufacturing process. We specialize in the following modalities and substances, mammalian and microbial-based therapeutic proteins, recombinant DNA, plasmid DNA (pDNA), viral vectors, messenger RNA (mRNA), and genetically engineered cells. Our services range from Process Development, Analytical Development, cGMP Manufacturing (both clinical and commercial), Quality Control, and Quality Assurance and Process Validation.


Bachem AG

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. With over 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.



Thermo Fisher Scientific

Thermo Fisher Scientific Inc is the world leader in serving science. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.


Molecular Targeting Technologies, Inc. (MTTI)

MTTI is a clinical stage company rooted in a decade of collaborative, global drug and diagnostics research. Our EvaThera™ platform of targeted radiotherapeutics and diagnostics for rare solid tumors is supported by a robust pipeline of other therapeutics and diagnostics and projected revenue from two out-licensed products. Multiple products are in human trials. All are backed by strong IP. MTTI is led by a seasoned team of former pharmaceutical industry executives.



LUCA Science Inc.

LUCA Science is a preclinical stage biopharmaceutical company pioneering a new class of mitochondrial therapy to restore cellular bioenergetics in dysfunctional or damaged tissues and organs. Mitochondria are the power plants in our cells that produce energy for our bodies. LUCA Science will use its platform technology to manufacture, store and deliver innovative mitochondrial drugs to research and development of therapeutics for unmet medical needs in a wide range of diseases for which there have been no effective treatments.


C4U Corporation

C4U is a privately held biotech company established in 2018. Our goal is to address unmet clinical needs by delivering safe and efficient gene therapies for genetic disorders though our proprietary NextGen CRISPR-Cas3 gene editing platform.

C4U owns an exclusive platform technology for the development of new gene therapies using CRISPR-Cas3 technology in the medical field, which is its primary focus area. We are seeking to strengthen our in-house pipelines with partnered projects and strategic alliances. We will also carry out joint research and technology licenses for applications in other fields benefiting from gene editing such as agriculture, fisheries, etc.


St Vincent’s Hospital Melbourne

As a leading tertiary academic health service, SVHM connects science, health and engineering to discover new ways of transforming health care and tackling our greatest health challenges.

SVHM recognizes the critical importance of collaboration in research and is an engaged partner with highest-ranked universities, medical research institutions, biotech industries, as well as collaboratives in the United States, UK and China. Our reputation for pursuing and applying new, evidence-based treatment options and innovative models of care, is what attracts the best and brightest to work and partner with us.



PiVOT is the leading local Contract Research Organization (CRO) in the Philippines. Despite only starting in 2019, we currently have over 100 employees and have recruited over 40,000 subjects for clinical trials through over 28 sites across the Philippines.

We are 100% owned by First Philippine Holdings Corp., a publicly-listed, Lopez-owned company, with assets of US$9B and attributable recurring net income of US$200M in power generation, real estate, construction, manufacturing, education, and healthcare.



ABVC BioPharma

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The Company has targeted its business to the stage of drug development that moves promising drugs from the laboratory to the market, the translational phase. Drugs considered by ABVC are usually derived from plants, address significant illnesses, and have successfully completed pre-clinical, disease animal model and Phase I safety studies at world-class research institutions.




OncoOne has overcome the previous limitations and challenges of targeting MIF by harnessing the high tumor-specificity of the disease-related and druggable isoform which the founders named the oxidized macrophage migration inhibitory factor or oxMIF. OncoOne is focused on developing two optimized mAbs to leverage the high-value potential of oxMIF as a target for the systemic treatment of hard-to-treat solid tumors including colorectal, ovarian and lung cancers as well as autoimmune disorders such arthritis, asthma, Crohn’s disease, ulcerative colitis, as well as rare autoimmune diseases.  Equipped with decades of drug development expertise and a uniquely deep understanding of the target itself, OncoOne is rapidly advancing both of their lead assets to clinic in 2023.
OncoOne is seeking Series B investors and strategic partners for the Asia-Pacific region to help develop and commercialize our novel immuno-oncology and immunology assets with blockbuster potential.



MediGear International Corp.

MediGear International Corporation (MGI) is an academia start-up from Tokyo Tech which challenges to solve the unmet medical needs such as solid cancers and chronic pains with quite a unique nanoparticle which is bio-compatible and degradable inside body and is not a medicine, but a medical device. As MGI is focusing R&D, its business model is license-out to contract manufacturer and distributors. 
MGI is in the early stage to prototype the device and to gather safety data, then to prove the concept in animals. MGI is looking for the investors and the collaboration partners including for the clinical trials.